Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas

Br J Dermatol. 2018 Apr;178(4):e273-e274. doi: 10.1111/bjd.16128. Epub 2018 Feb 22.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antipruritics / administration & dosage*
  • Aprepitant / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Lymphoma, T-Cell, Cutaneous / complications*
  • Pruritus / complications
  • Pruritus / drug therapy*
  • Retrospective Studies
  • Skin Neoplasms / complications*
  • Treatment Outcome

Substances

  • Antipruritics
  • Aprepitant